sort by Title |
sort by Date |
Download |
Bracketing and Matrixing Designs for Stability Testing of Drug Substances and Drug Products
The objective of this guideline is to provide harmonised guidance on the application of bracketing and matrixing for stability studies conducted in accordance with principles outlined in the ICH Q1A Harmonised Tripartite guideline covering Stability Testing of New Drug Substances and Products (hereafter referred to as the parent guideline).
|
2002-02-07 |
|
|
Impurities in New Drug Substances
This document is intended to provide guidance for registration applications on the content and qualification of impurities in new drug substances produced by chemical syntheses and not previously registered in a region or member state. ICH
|
2002-02-07 |
|
|
Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
This document is intended to provide guidance regarding good manufacturing practice (GMP) for the manufacturing of active pharmaceutical ingredients (APIs) under an appropriate system for managing quality. ICH
|
2000-11-10 |
|
|
Stability Testing of New Drug Substances and Products
The guideline addresses the information to be submitted in registration
applications for new molecular entities and associated drug products. ICH
|
2000-11-08 |
|
|
Impurities: Residual Solvents (Maintenance) PDE for Tetrahydrofuran
Concensus about new toxicity data for the solvent tetrahydrofuran (THF). ICH
|
2000-07-20 |
|
|
Impurities: Residual Solvents (maintenance) PDE for N-Methylpyrrolidone (NMP)
The document contains an analysis of an appropriate and more sensitive study from which to calculate a new PDE. ICH
|
2000-07-20 |
|
|
Impurities in New Drug Products
This document provides guidance recommendations for registration or marketing applications for marketing on the content and qualification of impurities in new Drug Products produced from chemically synthesised new drug substances not previously registered in a region or member state. ICH
|
1999-10-07 |
|
|
Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances
It provides guidance on the setting and justification of acceptance criteria and the
selection of test procedures for new drug substances of synthetic chemical origin,
and new drug products produced from them, which have not been registered
previously in the United States, the European Union, or Japan. ICH
|
1999-10-06 |
|
|
Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products
This guidance document provides general principles on the setting and justification, to the extent possible, of a uniform set of international specifications for biotechnological and biological products to support new marketing applications. ICH
|
1999-03-10 |
|
|
Impurities: Guideline for Residual Solvents
The objective of this guideline is to recommend acceptable levels of residual
solvents in pharmaceuticals for the safety of the patient. ICH
|
1997-07-17 |
|
|
Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products
The guideline provides broad guidance on appropriate standards for the derivation of human and animal cell lines and microbial cells to be used to prepare biotechnological/biological products defined in Section 1.3, Scope, and for the preparation and characterisation of cell banks to be used for production. ICH
|
1997-07-16 |
|
|
Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin
This document is concerned with testing and evaluation of the viral safety of biotechnology products derived from characterised cell lines of human or animal origin (i.e., mammalian, avian, insect) and outlines data that should be submitted in the marketing application/registration package. ICH
|
1997-03-05 |
|
|
Stability Testing: Photostability Testing of New Drug Substances and Products
The guideline primarily addresses the generation of photostability information for submission in Registration Applications for new molecular entities and associated drug products. ICH
|
1996-11-06 |
|
|
Stability Testing: Requirements for New Dosage Forms
This document is an annex to the ICH parent stability guideline and addresses recommendations on what should be submitted regarding stability of new dosage forms by the owner of the original application, after the original submission for new drug substances and products. ICH
|
1996-06-11 |
|
|
Validation of Analytical Procedures: Methodology
This document is complementary to the parent document which presents a discussion of the characteristics that should be considered during the validation of analytical procedures. Its purpose is to provide some guidance and recommendations on how to consider the various validation characteristics for each analytical procedure. ICH
|
1996-06-11 |
|
|
Guideline for Good Clinical Practice
The objective of this ICH GCP Guideline is to provide a unified standard for the
European Union (EU), Japan and the United States to facilitate the mutual
acceptance of clinical data by the regulatory authorities in these jurisdictions.
|
1996-05-01 |
|
|
Quality fast Biotechnological Products: Stability Testing of Biotechnological/Biological Products
The guidance stated in this annex applies to well-characterised proteins and polypeptides, their derivatives and products of which they are components, and which are isolated from tissues, body fluids, cell cultures, or produced using rDNA
technology. ICH
|
1995-11-30 |
|
|
Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of R-DNA Derived Protein Products
This document provides guidance on the characterisation of the
expression construct for the production of recombinant DNA protein products in eukaryotic and prokaryotic cells. ICH
|
1995-11-30 |
|
|
Text on Validation of Analitical Procedures
This document presents a discussion of the characteristics for consideration during the validation of the analytical procedures included as part of registration applications submitted within the EC, Japan and USA. ICH
|
1994-10-27 |
|